Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Abarceo AB holds a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action, which is the only active prosecution item for the company. This indicates a highly focused effort to secure patent protection for a specific biotechnology or pharmaceutical innovation.
The examination is conducted by 1 distinct examiner. This examiner is located within 1 distinct art unit, suggesting that the company's current filings are being reviewed within a specialized technical group. MOU, LIYUAN is the busiest examiner for the portfolio. This examiner is currently overseeing the 1 pending office action that is active.
With a busiest examiner pending count of 1, the company's prosecution activity is entirely concentrated under one individual. This allows for a streamlined and focused legal strategy when interacting with the 1 distinct examiner. However, it also means that the company's immediate progress in the Biotechnology & Pharmaceuticals sector is tied to the resolution of this single pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040040 | NOVEL VDAC1 INHIBITORS | MOU, LIYUAN | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18040040 | NOVEL VDAC1 INHIBITORS | MOU, LIYUAN | 1628 | §103 | Final Rejection | 31d overdue | Pending | Jan 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial